Moderna and Merck Report Melanoma Vaccine Success in Large Trial
Moderna and Merck report their personalized mRNA melanoma vaccine succeeded in a large clinical trial, a milestone for mRNA cancer immunotherapy in skin cancer.
Topic
Merck
Topic
Merck
Moderna-Merck mRNA Vaccine Succeeds in Late-Stage Melanoma Trial
Moderna and Merck said their mRNA cancer vaccine succeeded in a late-stage melanoma trial, per statnews.com, but effect size, end…
Tulisokibart posts first positive Phase II anti-TL1A read-out
Merck's tulisokibart produced the first positive Phase II efficacy data for an anti-TL1A antibody in a dermatologic indication, o…
Merck's tulisokibart hits primary endpoint in Phase II TL1A trial
Merck's tulisokibart met its primary endpoint in the first Phase II anti-TL1A dermatology trial, per The Pharma Letter — a first-…
Tulisokibart Hits HiSCR50 Endpoint in Phase 2b Hidradenitis Suppurativa Trial
High-dose tulisokibart reached HiSCR50 in 72% of HS patients at week 16 vs 35% on placebo in Merck's phase 2b MK-7240-012 trial,…
Merck Reports First Positive Phase 3 for Personalized mRNA Melanoma Therapy
Merck posts the first positive Phase 3 result for a personalized mRNA melanoma therapy, advancing individualized neoantigen immun…
Moderna and Merck Cancer Vaccine Breakthrough Reported
A Moderna and Merck breakthrough could trigger a wave of cancer vaccine development, CNN reports — an advance dermatology is watc…
Moderna and Merck Revive mRNA Prospects With Melanoma Success
Moderna and Merck report a melanoma success that revives hopes for mRNA technology, pointing toward personalized cancer vaccines…